Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

33.3%

2 terminated/withdrawn out of 6 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
6(100.0%)
6Total
Phase 1(6)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT02575794Phase 1Completed

Terameprocol in Treating Patients With Recurrent High Grade Glioma

Role: collaborator

NCT00154089Phase 1Completed

A Pilot Study of EM-1421 for the Treatment of Cervical Intraepithelial Neoplasia

Role: lead

NCT00664677Phase 1Terminated

Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia

Role: lead

NCT00057512Phase 1Completed

Study of Intralesional Injection of M4N in Patients With Refractory Malignant Tumors of the Head and Neck

Role: lead

NCT00664586Phase 1Terminated

A Phase 1 Continuous Intravenous Infusion Study of Terameprocol (EM-1421) in Subjects With Refractory Solid Tumors

Role: lead

NCT00259818Phase 1Completed

Dose Escalation Study of EM-1421 for the Treatment of Recurrent or Refractory Solid Tumors

Role: lead

All 6 trials loaded